Axonal elongation is one of the hallmarks of neuronal polarization. This phenomenon requires axonal membrane growth by exocytosis of plasmalemmal precursor vesicles (PPVs) at the nerve growth cone, a process regulated by IGF-1 activation of the PI3K (phosphatidylinositol-3 kinase) pathway. Few details are known, however, about the targeting mechanisms for PPVs. Here, we show, in cultured hippocampal pyramidal neurons and growth cones isolated from fetal rat brain, that IGF-1 activates the GTP-binding protein TC10, which triggers translocation to the plasma membrane of the exocyst component exo70 in the distal axon and growth cone. We also show that TC10 and exo70 function are necessary for addition of new membrane and, thus, axon elongation stimulated by IGF-1. Moreover, expression silencing of either TC10 or exo70 inhibit the establishment of neuronal polarity by hindering the insertion of IGF-1 receptor in one of the undifferentiated neurites. We conclude that, in hippocampal pyramidal neurons in culture, (1) membrane expansion at the axonal growth cone is regulated by IGF-1 via a cascade involving TC10 and the exocyst complex, (2) TC10 and exo70 are essential for the polarized externalization of IGF-1 receptor, and (3) this process is necessary for axon specification.
Neonatal hypoxic-ischemic encephalopathy (HIE) is the most common cause of death and long-term disabilities in term neonates. Caffeine exerts anti-inflammatory effects and has been used in neonatal intensive care units in recent decades. In our neonatal rat model of hypoxic-ischemic (HI) brain injury, we demonstrated that a single daily dose of caffeine (40 mg/kg) for 3 days post-HI reduced brain tissue loss and microgliosis compared to the vehicle group. The AMPK/mTOR pathway plays an important role in sensing the stress responses following brain injury. However, the role of mTOR in HI-associated brain damage remains unclear. A detailed analysis of the AMPK/mTOR pathway in our model revealed that this pathway plays a key role in hypoxia-regulated neuroprotection and can be significantly influenced by caffeine treatment. Targeting HI with caffeine might offer effective neuroprotection, reduce mortality, and improve functional outcomes in patients with HIE, especially in low- and middle-income countries, where neuroprotective treatment is urgently needed.
Hypoxic-ischemic encephalopathy (HIE), resulting from a lack of blood flow and oxygen before or during newborn delivery, is a leading cause of cerebral palsy and neurological disability in children. Therapeutic hypothermia (TH), the current standard of care in HIE, is only beneficial in 1 of 7–8 cases. Therefore, there is a critical need for more efficient treatments. We have previously reported that omega-3 (n-3) fatty acids (FA) carried by triglyceride (TG) lipid emulsions provide neuroprotection after experimental hypoxic-ischemic (HI) injury in neonatal mice. Herein, we propose a novel acute therapeutic approach using an n-3 diglyceride (DG) lipid emulsions. Importantly, n-3 DG preparations had much smaller particle size compared to commercially available or lab-made n-3 TG emulsions. We showed that n-3 DG molecules have the advantage of incorporating at substantially higher levels than n-3 TG into an in vitro model of phospholipid membranes. We also observed that n-3 DG after parenteral administration in neonatal mice reaches the bloodstream more rapidly than n-3 TG. Using neonatal HI brain injury models in mice and rats, we found that n-3 DG emulsions provide superior neuroprotection than n-3 TG emulsions or TH in decreasing brain infarct size. Additionally, we found that n-3 DGs attenuate microgliosis and astrogliosis. Thus, n-3 DG emulsions are a superior, promising, and novel therapy for treating HIE.
Einleitung Die hypoxisch-ischämische Enzephalopathie (HIE) ist die häufigste Ursache für Tod und langfristige Behinderung bei reifen Neugeborenen. Die aktuelle einzig verfügbare Therapie ist die therapeutische Hypothermie (TH). Dennoch sind sichere und wirksame Zusatztherapien erforderlich, um die Ergebnisse zu optimieren. Coffein ist ein Methylxanthin, das seit mehr als 30 Jahren auf der neonatalen Intensivstation zur Behandlung der neonatalen Apnoe eingesetzt wird. Coffein hat eine antioxidative, entzündungshemmende und antiapoptotische Wirkung. Während die meisten Studien bei neonataler Apnoe durchgeführt wurden, ist die potenzielle Rolle von Coffein bei der Vorbeugung von Entwicklungsstörungen des Gehirns nach HIE kaum bekannt. Ziel dieser Studie war es, die richtige Dosiskonzentration im Rahmen der HIE, mit oder ohne TH, zu ermitteln, die einen neuroprotektiven Effekt im experimentellen neonatalen HIE-Modell zeigt.
To study the prion-like behavior of misfolded alpha-synuclein, mouse models are needed that allow fast and simple transmission of alpha-synuclein prionoids, which cause neuropathology within the central nervous system (CNS). Here we describe that intraglossal or intraperitoneal injection of alpha-synuclein fibrils into bigenic Tg(M83+/-:Gfap-luc+/-) mice, which overexpress human alpha-synuclein with the A53T mutation from the prion protein promoter and firefly luciferase from the promoter for glial fibrillary acidic protein (Gfap), is sufficient to induce neuropathologic disease. In comparison to homozygous Tg(M83+/+) mice that develop severe neurologic symptoms beginning at an age of 8 months, heterozygous Tg(M83+/-:Gfap-luc+/-) animals remain free of spontaneous disease until they reach an age of 22 months. Interestingly, injection of alpha-synuclein fibrils via the intraperitoneal route induced neurologic disease with paralysis in four of five Tg(M83+/-:Gfap-luc+/-) mice with a median incubation time of 229 ±17 days. Diseased animals showed severe deposits of phosphorylated alpha-synuclein in their brains and spinal cords. Accumulations of alpha-synuclein were sarkosyl-insoluble and colocalized with ubiquitin and p62, and were accompanied by an inflammatory response resulting in astrocytic gliosis and microgliosis. Surprisingly, inoculation of alpha-synuclein fibrils into the tongue was less effective in causing disease with only one of five injected animals showing alpha-synuclein pathology after 285 days. Our findings show that inoculation via the intraglossal route and more so via the intraperitoneal route is suitable to induce neurologic illness with relevant hallmarks of synucleinopathies in Tg(M83+/-:Gfap-luc+/-) mice. This provides a new model for studying prion-like pathogenesis induced by alpha-synuclein prionoids in greater detail.
Intrapartum hypoxia-ischemia leading to neonatal encephalopathy (NE) results in significant neonatal mortality and morbidity worldwide, with > 85% of cases occurring in low- and middle-income countries (LMIC). Therapeutic hypothermia (HT) is currently the only available safe and effective treatment of HIE in high-income countries (HIC); however, it has shown limited safety or efficacy in LMIC. Therefore, other therapies are urgently required. We aimed to compare the treatment effects of putative neuroprotective drug candidates following neonatal hypoxic-ischemic (HI) brain injury in an established P7 rat Vannucci model. We conducted the first multi-drug randomized controlled preclinical screening trial, investigating 25 potential therapeutic agents using a standardized experimental setting in which P7 rat pups were exposed to unilateral HI brain injury. The brains were analysed for unilateral hemispheric brain area loss after 7 days survival. Twenty animal experiments were performed. Eight of the 25 therapeutic agents significantly reduced brain area loss with the strongest treatment effect for Caffeine, Sonic Hedgehog Agonist (SAG) and Allopurinol, followed by Melatonin, Clemastine, ß-Hydroxybutyrate, Omegaven, and Iodide. The probability of efficacy was superior to that of HT for Caffeine, SAG, Allopurinol, Melatonin, Clemastine, ß-hydroxybutyrate, and Omegaven. We provide the results of the first systematic preclinical screening of potential neuroprotective treatments and present alternative single therapies that may be promising treatment options for HT in LMIC.
Melatonin has been shown to be neuroprotective in different animal models of neonatal hypoxic-ischemic brain injury. However, its exact molecular mechanism of action remains unknown. Our aim was to prove melatonin's short- and long-term neuroprotection and investigate its role on the AMPK (AMP-activated protein kinase)/mTOR (mammalian target of rapamycin) pathway following neonatal hypoxic-ischemic brain injury.
Hypoxic-ischemic encephalopathy (HIE) is a common type of brain injury caused by a lack of oxygen and blood flow to the brain during the perinatal period. The incidence of HIE is approximately 2−3 cases per 1000 live births in high-income settings; while in low- and middle-income countries, the incidence is 3−10-fold higher. Therapeutic hypothermia (TH) is the current standard treatment for neonates affected by moderate−severe HIE. However, more than 50% of all infants with suspected HIE have mild encephalopathy, and these infants are not treated with TH because of their lower risk of adverse outcomes. Despite this, several analyses of pooled data provide increasing evidence that infants who initially have mild encephalopathy may present signs of more significant brain injury later in life. The purpose of this study was to expand our knowledge about the effect of mild−moderate hypoxia-ischemia (HI) at the cellular, structural, and functional levels. An established rat model of mild−moderate HI was used, where postnatal day (P) 7 rats were exposed to unilateral permanent occlusion of the left carotid artery and 90 min of 8% hypoxia, followed by TH or normothermia (NT) treatment. The extent of injury was assessed using histology (P14 and P42) and MRI (P11 and P32), as well as with short-term and long-term behavioral tests. Neurogenesis was assessed by BrdU staining. We showed that mild−moderate HI leads to a progressive loss of brain tissue, pathological changes in MRI scans, as well as an impairment of long-term motor function. At P14, the median area loss assessed by histology for HI animals was 20% (p < 0.05), corresponding to mild−moderate brain injury, increasing to 55% (p < 0.05) at P42. The data assessed by MRI corroborated our results. HI led to a decrease in neurogenesis, especially in the hippocampus and the lateral ventricle at early time points, with a delayed partial recovery. TH was not neuroprotective at early time points following mild−moderate HI, but prevented the increase in brain damage over time. Additionally, rats treated with TH showed better long-term motor function. Altogether, our results bring more light to the understanding of pathophysiology following mild-moderate HI. We showed that, in the context of mild-moderate HI, TH failed to be significantly neuroprotective. However, animals treated with TH showed a significant improvement in motor, but not cognitive long-term function. These results are in line with what is observed in some cases where neonates with mild HIE are at risk of neurodevelopmental deficits in infancy or childhood. Whether TH should be used as a preventive treatment to reduce adverse outcomes in mild-HIE remains of active interest, and more research has to be carried out in order to address this question.
The formation of complex dendritic arbors is crucial for the assembly of functional networks as abnormal dendrite formation underlies several neurodevelopmental and psychiatric disorders. Many extracellular factors have been postulated as regulators of dendritic growth. Wnt proteins play a critical role in neuronal development and circuit formation. We previously demonstrated that Wnt7b acts through the scaffold protein dishevelled 1 (Dvl1) to modulate dendrite arborisation by activating a non-canonical Wnt signalling pathway. Here, we identify the seven-transmembrane frizzled-7 (Fz7, also known as FZD7) as the receptor for Wnt7b-mediated dendrite growth and complexity. Importantly, Fz7 is developmentally regulated in the intact hippocampus, and is localised along neurites and at dendritic growth cones, suggesting a role in dendrite formation and maturation. Fz7 loss-of-function studies demonstrated that Wnt7b requires Fz7 to promote dendritic arborisation. Moreover, in vivo Fz7 loss of function results in dendritic defects in the intact mouse hippocampus. Furthermore, our findings reveal that Wnt7b and Fz7 induce the phosphorylation of Ca2+/calmodulin-dependent protein kinase II (CaMKII) and JNK proteins, which are required for dendritic development. Here, we demonstrate that Wnt7b-Fz7 signals through two non-canonical Wnt pathways to modulate dendritic growth and complexity.
'/%3e%3cuse xlink:href='%23a' transform='rotate(45 400 250)'/%3e%3cuse xlink:href='%23a' transform='rotate(67.5 400 250)'/%3e%3cpath id='b' fill='%2385340a' d='M404.31 274.41c.453 9.054 5.587 13.063 4.579 21.314 2.213-6.525-3.124-11.583-2.82-21.22m-7.649-23.757 19.487 42.577-16.329-43.887'/%3e%3cuse xlink:href='%23b' transform='rotate(22.5 400 250)'/%3e%3cuse xlink:href='%23b' transform='rotate(45 400 250)'/%3e%3cuse xlink:href='%23b' transform='rotate(67.5 400 250)'/%3e%3c/g%3e%3cuse xlink:href='%23c' transform='rotate(90 400 250)'/%3e%3cuse xlink:href='%23c' transform='rotate(180 400 250)'/%3e%3cuse xlink:href='%23c' transform='rotate(270 400 250)'/%3e%3ccircle cx='400' cy='250' r='27.778' fill='%23f6b40e' stroke='%2385340a' stroke-width='1.5'/%3e%3cpath id='h' fill='%23843511' d='M409.47 244.06c-1.897 0-3.713.822-4.781 2.531 2.136 1.923 6.856 2.132 10.062-.219a7.333 7.333 0 0 0-5.281-2.312zm-.031.438c1.846-.034 3.571.814 3.812 1.656-2.136 2.35-5.55 2.146-7.687.437.935-1.495 2.439-2.067 3.875-2.094z'/%3e%3cuse xlink:href='%23d' transform='matrix(-1 0 0 1 800.25 0)'/%3e%3cuse xlink:href='%23e' transform='matrix(-1 0 0 1 800.25 0)'/%3e%3cuse xlink:href='%23f' transform='translate(18.862)'/%3e%3cuse xlink:href='%23g' transform='matrix(-1 0 0 1 800.25 0)'/%3e%3cpath fill='%2385340a' d='M395.75 253.84c-.913.167-1.563.977-1.563 1.906 0 1.062.878 1.906 1.938 1.906a1.89 1.89 0 0 0 1.563-.812c.739.556 1.764.615 2.312.625.084.002.193 0 .25 0 .548-.01 1.573-.069 2.313-.625.36.516.935.812 1.562.812 1.06 0 1.938-.844 1.938-1.906 0-.929-.65-1.74-1.563-1.906.513.18.844.676.844 1.219a1.28 1.28 0 0 1-1.281 1.281c-.68 0-1.242-.54-1.282-1.219-.208.417-1.034 1.655-2.656 1.719-1.622-.064-2.447-1.302-2.656-1.719-.04.679-.6 1.219-1.281 1.219a1.28 1.28 0 0 1-1.281-1.281c0-.542.33-1.038.843-1.219zm2.09 5.69c-2.138 0-2.983 1.937-4.906 3.219 1.068-.427 1.91-1.27 3.406-2.125 1.496-.855 2.772.187 3.625.187h.031c.853 0 2.13-1.041 3.625-.187 1.497.856 2.369 1.698 3.438 2.125-1.924-1.282-2.8-3.219-4.938-3.219-.426 0-1.271.23-2.125.656h-.031c-.853-.426-1.698-.656-2.125-.656z'/%3e%3cpath fill='%2385340a' d='M397.12 262.06c-.844.037-1.96.207-3.563.688 3.848-.855 4.697.437 6.407.437h.03c1.71 0 2.56-1.292 6.407-.438-4.274-1.282-5.124-.437-6.406-.437h-.031c-.802 0-1.437-.312-2.844-.25z'/%3e%3cpath fill='%2385340a' d='M393.75 262.72c-.248.003-.519.005-.813.031 4.488.428 2.331 3 7.032 3h.03c4.702 0 2.575-2.572 7.063-3-4.7-.426-3.214 2.344-7.062 2.344h-.031c-3.608 0-2.496-2.421-6.22-2.375zm10.1 6.94a3.848 3.848 0 0 0-3.846-3.846 3.848 3.848 0 0 0-3.847 3.846 3.955 3.955 0 0 1 3.847-3.04 3.952 3.952 0 0 1 3.846 3.04z'/%3e%3cpath id='e' fill='%2385340a' d='M382.73 244.02c4.915-4.273 11.11-4.915 14.53-1.709.837 1.121 1.373 2.32 1.593 3.57.43 2.433-.33 5.062-2.236 7.756.215-.001.643.212.856.427 1.697-3.244 2.297-6.577 1.74-9.746a13.815 13.815 0 0 0-.67-2.436c-4.7-3.845-11.11-4.272-15.81 2.138z'/%3e%3cpath id='d' fill='%2385340a' d='M390.42 242.74c2.777 0 3.419.642 4.7 1.71 1.284 1.068 1.924.854 2.137 1.068.213.215 0 .854-.426.64s-1.284-.64-2.564-1.708c-1.283-1.07-2.563-1.069-3.846-1.069-3.846 0-5.983 3.205-6.41 2.991-.426-.214 2.137-3.632 6.41-3.632z'/%3e%3cuse xlink:href='%23h' transform='translate(-19.181)'/%3e%3ccircle id='f' cx='390.54' cy='246.15' r='1.923' fill='%2385340a'/%3e%3cpath id='g' fill='%2385340a' d='M385.29 247.44c3.633 2.778 7.265 2.564 9.402 1.282 2.136-1.282 2.136-1.709 1.71-1.709-.427 0-.853.427-2.564 1.281-1.71.856-4.273.856-8.546-.854z'/%3e%3c/svg%3e)
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)